The new ATM creates persistent overhang; monitor periodic disclosures for actual sales. The termination of the prior undrawn facility is neutral. Watch for any pipeline catalysts that could offset dilution concerns.
Price Chart
Executive Summary
Climb Bio entered into a new at-the-market (ATM) equity distribution agreement with Jefferies LLC for up to $100 million in common stock, replacing a prior undrawn ATM facility with Oppenheimer. The new facility represents potential dilution of ~16% of current market cap and signals ongoing cash needs for a pre-revenue biotech.
Key Facts
- New ATM agreement with Jefferies LLC for up to $100 million of common stock
- Prior Oppenheimer ATM facility (up to $22.35 million) terminated with zero shares sold
- Jefferies will receive a 3% selling commission on gross proceeds
- The company is a pre-revenue clinical-stage biotech with $625 million market cap
Financial Impact
Potential dilution of up to 16% of current float if the full $100 million is sold at current prices
Risk Factors
- Potential staggered equity sales may pressure stock price
- Pre-revenue status with no near-term revenue catalysts
- Executive departure 4 days prior adds uncertainty
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-269567 |
| Document: d92589d8k.htm | 0001193125-26-269567 |
| Document: d92589dex51.htm | 0001193125-26-269567 |
| Document: 0001193125-26-269567-index-headers.html | 0001193125-26-269567 |
| Document: 0001193125-26-269567-index.html | 0001193125-26-269567 |
| Document: 0001193125-26-269567.txt | 0001193125-26-269567 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $10.92 | awaiting T+1 | — | $8.81 (−19.32%) |
Oct 23, 2026 3d ago | 8-K | $10.47 | awaiting T+1 | — | $8.81 (−15.85%) |
Oct 23, 2026 3d ago | Press Release | $10.34 | awaiting T+1 | — | $8.81 (−14.80%) |
Sep 22, 2026 4w ago | Institutional Cluster | $14.21 $12.52 | ▼ −11.89% | ▼ −11.17% | $8.81 (−38.00%) |
Sep 3, 2026 7w ago | 8-K | $14.59 $15.52 | ▲ +6.37% | ▲ +6.76% | $8.81 (−39.62%) |
Aug 14, 2026 10w ago | 8-K | $16.33 $17.44 | ▲ +6.80% | ▲ +7.27% | $8.81 (−46.05%) |
Aug 6, 2026 11w ago | 8-K | $14.00 $14.00 | · 0.00% | ▼ −0.61% | $8.81 (−37.07%) |
Jun 30, 2026 16w ago | 144 | $13.29 $12.90 | ▼ −2.93% | ▼ −2.80% | $8.81 (−33.71%) |
Jun 12, 2026 19w ago | 8-K | $11.49 $10.71 | ▲ +6.79% | ▲ +6.19% | $8.81 (+23.32%) |
Jun 12, 2026 19w ago | 424B5 | $11.49 $10.71 | ▲ +6.79% | ▲ +6.19% | $8.81 (+23.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers